abstract: BACKGROUND: A low @entity4 ( @entity5 )/ @entity2 (AA) ratio is known to be associated with cardiovascular events. However, the relationship between the @entity5 /AA ratio and coronary plaque vulnerability assessed by optical coherence tomography (OCT) has not been examined thoroughly. This study examined the relationship between the @entity5 /AA ratio and coronary plaque vulnerability assessed by OCT in @entity0 with @entity1 ( @entity1 ). METHODS: We evaluated 59 @entity1 @entity0 who had undergone percutaneous coronary intervention using OCT. We divided them into 2 groups according to OCT findings-those with and without thin-cap @entity3 (TCFA)-and compared the @entity5 /AA ratio between the groups. RESULTS: We identified 32 and 27 @entity0 with and without TCFA, respectively. The @entity5 /AA ratio was significantly lower in @entity0 with TCFA than in those without TCFA [0.35, interquartile range (0.21-0.44) vs. 0.54, interquartile range (0.42-0.70); p<0.001]. In multivariate logistic regression analysis, the @entity5 /AA ratio was an independent predictor of TCFA (odds ratio, 0.09; 95% confidence interval, 0.007-0.99; p=0.049). The @entity5 /AA ratio and fibrous cap thickness showed a significant positive correlation (Spearman   =0.46; p<0.001). Furthermore, receiver operating characteristic curve analysis showed that an @entity5 /AA ratio<0.46 could predict TCFA (81.3%, sensitivity; 74.1%, specificity). CONCLUSIONS: A low serum @entity5 /AA ratio is significantly associated with coronary plaque vulnerability assessed by OCT in @entity1 @entity0 .

title: Low @entity4 to XXXX ratio is associated with thin-cap @entity3 determined by optical coherence tomography.

answer: @entity2


abstract: BACKGROUND: A low @entity4 ( @entity5 )/ @entity2 (AA) ratio is known to be associated with cardiovascular events. However, the relationship between the @entity5 /AA ratio and coronary plaque vulnerability assessed by optical coherence tomography (OCT) has not been examined thoroughly. This study examined the relationship between the @entity5 /AA ratio and coronary plaque vulnerability assessed by OCT in @entity0 with @entity1 ( @entity1 ). METHODS: We evaluated 59 @entity1 @entity0 who had undergone percutaneous coronary intervention using OCT. We divided them into 2 groups according to OCT findings-those with and without thin-cap @entity3 (TCFA)-and compared the @entity5 /AA ratio between the groups. RESULTS: We identified 32 and 27 @entity0 with and without TCFA, respectively. The @entity5 /AA ratio was significantly lower in @entity0 with TCFA than in those without TCFA [0.35, interquartile range (0.21-0.44) vs. 0.54, interquartile range (0.42-0.70); p<0.001]. In multivariate logistic regression analysis, the @entity5 /AA ratio was an independent predictor of TCFA (odds ratio, 0.09; 95% confidence interval, 0.007-0.99; p=0.049). The @entity5 /AA ratio and fibrous cap thickness showed a significant positive correlation (Spearman   =0.46; p<0.001). Furthermore, receiver operating characteristic curve analysis showed that an @entity5 /AA ratio<0.46 could predict TCFA (81.3%, sensitivity; 74.1%, specificity). CONCLUSIONS: A low serum @entity5 /AA ratio is significantly associated with coronary plaque vulnerability assessed by OCT in @entity1 @entity0 .

title: Low @entity4 to @entity2 ratio is associated with thin-cap XXXX determined by optical coherence tomography.

answer: @entity3


abstract: PURPOSE: Cancer control of partial nephrectomy for high-risk localized @entity4 is unclear. To assess whether @entity5 provides adequate @entity1 control in @entity2 ( @entity6 ), survival outcomes were compared in both a population-based cohort and an institutional cohort. METHODS: Surveillance, Epidemiology, and End Results database and a prospectively maintained institutional database were queried for @entity0 with @entity4 who underwent @entity5 or RN for a localized @entity1  <=7  cm and were found to have @entity6 ( @entity6 ). Cancer-specific (CSS) or @entity3 ( @entity3 ) and @entity3 ( @entity3 ) were primary outcomes measured and were compared between those who underwent @entity5 and RN using multivariable Cox proportional hazards and propensity analysis. RESULTS: The population cohort consisted of 12,757 (24.9  %) @entity0 with @entity6 , 85.2 and 14.8  % of which underwent RN and @entity5 , respectively. RN was not associated with CSS (HR 1.23, p  =  0.08) but was independently associated with poor @entity3 (HR 1.16, p  =  0.031). Propensity analysis showed that RN resulted in a 20  % increased risk of death from all causes (p  =  0.008). In the institutional cohort, of 317 @entity0 , 35.9  % had @entity6 , 56 and 52 of which underwent RN and @entity5 , respectively. Adjusting for age-adjusted Charlson index, RN was a predictor of poor @entity3 (OR 6.20, p  =  0.041). Propensity analysis showed that @entity3 and @entity3 were not related to nephrectomy type (RN HR 0.65, p  =  0.627 and RN HR 1.70, p  =  0.484). CONCLUSIONS: In @entity0 with pathologic high-risk @entity4 , partial excision is associated with similar @entity1 control as compared to radical excision.

title: Cancer control of partial nephrectomy for high-risk localized XXXX : population-based and single-institutional analysis.

answer: @entity4


abstract: From July 1988 through September 1993, 30 neonates with symptomatic @entity2 underwent complete repair. Sixteen @entity0 had tetralogy and @entity5 , 9 had @entity6 , 3 had @entity4 , and 2 had both @entity6 and @entity4 . The median age at operation was 11 days (mean +/- standard error of the mean, 12.6 +/- 2.9 days), with a mean weight of 3.1 +/- 0.1 kg (range 1.5 to 4.4 kg). Preoperatively, 14 @entity0 were receiving an infusion of prostaglandin, 13 were mechanically ventilated, and 6 required inotropic support. Right ventricular outflow tract obstruction was managed by a limited transannular patch in 25 @entity0 , infundibular muscle division with limited resection in 15, and insertion of a right ventricle-pulmonary artery valved aortic homograft conduit in 5 @entity0 . Follow-up was complete at a median interval of 24 months (range 1 to 62 months). There were no hospital @entity1 and two late @entity1 , for 1-month, 1-year, and 5-year actuarial survivals of 100%, 93%, and 93%, respectively. The hazard function for @entity1 had a rapidly declining single phase that approached zero by 6 months after the operation. Both late @entity1 occurred in @entity0 with @entity2 and @entity6 who had undergone aortic homograft conduit reconstruction, so that the only independent risk factor for @entity1 was the use of a valved homograft conduit (p < or = 0.005). Eight @entity0 required reoperation, resulting in 1-month, 1-year, and 5-year freedom from reoperation rates of 100%, 93%, and 66%, respectively. Indications for reoperation were branch left @entity5 in 5 @entity0 , residual right ventricular outflow tract obstruction in 2 @entity0 , and severe @entity3 in 1 @entity0 . Independent risk factors for reoperation included an intraoperative pressure ratio between the right and left ventricles of 0.75 or greater (p = 0.01), Doppler residual left @entity5 of 15 mm Hg or more, or Doppler right ventricular outflow tract obstruction gradient of 40 mm Hg or more at hospital discharge (p = 0.002 and 0.02, respectively). This series demonstrates the safety of early hemodynamic repair of symptomatic @entity2 in neonates. It also emphasizes the importance of relieving all sources of right ventricular outflow tract obstruction at the initial operation, particularly that located at the site of insertion of the ductus arteriosus, which may be difficult to diagnose in the neonate before ductal closure occurs. The safety and efficacy of valved aortic homograft conduits in neonates requires further investigation.

title: Intermediate results after complete repair of XXXX in neonates.

answer: @entity2


abstract: @entity3 from @entity1 are infrequent, and their diagnosis and management can be extremely difficult. Over the past 10 years we treated 13 @entity0 with major @entity3 from @entity1 . Twelve had been involved in motor vehicle collisions, none of whom were wearing seat belts. One @entity0 was injured in an assault. Only five @entity0 had physical findings suggesting @entity4 . Serum amylase levels were elevated in seven of the nine @entity0 (78%) in whom this test was obtained. Computed tomography scans demonstrated @entity3 in three of the four @entity0 in whom it was performed. The five @entity0 in whom peritoneal lavage was performed had free intraperitoneal blood from @entity4 . One injury was diagnosed by ultrasound. Injuries were equally distributed throughout the pancreas, with two @entity1 in the head, three in the body, five in the tail, and three with @entity1 in both the head and the body. Five @entity0 had @entity1 . All @entity0 underwent celiotomy. Eight @entity0 required no operative management of their @entity3 other than drainage. Injury Severity Score averaged 28.5 +/- 2.6 (mean +/- standard error), and mean hospital stay was 31 +/- 9.8 days. One @entity0 with delayed diagnosis of a @entity3 developed a @entity5 , but all other complications and prolonged hospitalizations were due to @entity2 , chest, other abdominal organs, or extremities. All @entity0 survived. The diagnosis of blunt @entity3 requires a high index of suspicion, and diagnostic studies may demonstrate only subtle signs of injury. Most @entity1 can be managed by localized resection and/or drainage.(ABSTRACT TRUNCATED AT 250 WORDS)

title: XXXX from @entity1 .

answer: @entity3


abstract: @entity3 from @entity1 are infrequent, and their diagnosis and management can be extremely difficult. Over the past 10 years we treated 13 @entity0 with major @entity3 from @entity1 . Twelve had been involved in motor vehicle collisions, none of whom were wearing seat belts. One @entity0 was injured in an assault. Only five @entity0 had physical findings suggesting @entity4 . Serum amylase levels were elevated in seven of the nine @entity0 (78%) in whom this test was obtained. Computed tomography scans demonstrated @entity3 in three of the four @entity0 in whom it was performed. The five @entity0 in whom peritoneal lavage was performed had free intraperitoneal blood from @entity4 . One injury was diagnosed by ultrasound. Injuries were equally distributed throughout the pancreas, with two @entity1 in the head, three in the body, five in the tail, and three with @entity1 in both the head and the body. Five @entity0 had @entity1 . All @entity0 underwent celiotomy. Eight @entity0 required no operative management of their @entity3 other than drainage. Injury Severity Score averaged 28.5 +/- 2.6 (mean +/- standard error), and mean hospital stay was 31 +/- 9.8 days. One @entity0 with delayed diagnosis of a @entity3 developed a @entity5 , but all other complications and prolonged hospitalizations were due to @entity2 , chest, other abdominal organs, or extremities. All @entity0 survived. The diagnosis of blunt @entity3 requires a high index of suspicion, and diagnostic studies may demonstrate only subtle signs of injury. Most @entity1 can be managed by localized resection and/or drainage.(ABSTRACT TRUNCATED AT 250 WORDS)

title: @entity3 from XXXX .

answer: @entity1


abstract: The density and distribution of Merkel cells in @entity0 embryonic and fetal skin were studied using an immunolabeling technique on epidermal and dermal sheets obtained by @entity1 separation. Merkel cells were identified by the known cytokeratin markers @entity2 and @entity3 . Merkel cells showed @entity2 immunoreactivity as early as 56 d estimated gestational age (EGA) in the palmar epidermis (133.11 +/- 44.27 cells/mm2). The density increased rapidly, reaching a maximum of more than 1400 cells/mm2 at 80-90 d EGA. At this stage, the cells became distributed along the primary epidermal ridges. In the palmar epidermis of fetuses older than 100 d EGA, the distribution of Merkel cells showed the same pattern, but the density then decreased gradually. Merkel cells were not observed in ductal and glandular portions of eccrine sweat glands. In the epidermal sheets of hairy skin, a few cells were first seen in the fetus at 75 d EGA. At 100 d EGA, only a few Merkel cells were observed, mostly in the hair pegs and bulbous hair pegs. In the older fetus, ring-like arrangements and aggregates of Merkel cells were prominent in the infundibulum and bulge of hair follicles, respectively. Merkel cells were both globular and dendritic in shape. The ratio of dendritic to globular cells increased gradually until the period of highest Merkel cell density in both the glabrous and hairy skin. All Merkel cells located in the dermis were globular in shape. In accord with the results obtained, we postulate that Merkel cells may have some functional role in the formation and proliferation of eccrine sweat glands and hair follicle anlagen in developing skin.

title: The appearance, density, and distribution of Merkel cells in XXXX embryonic and fetal skin: their relation to sweat gland and hair follicle development.

answer: @entity0


abstract: OBJECTIVE: Uterine @entity4 (UCSs) are aggressive @entity1 previously considered to be @entity2 , but now recognized as @entity1 composed of metaplastic transformation of epithelial elements. Much of the management for UCS has been extrapolated from studies of @entity3 and @entity2 . This article critically reviews the literature pertinent to the pathology, pathogenesis, diagnosis and management of @entity0 with UCS. METHODS: MEDLINE was searched for English language literature on UCS with a focus on the past 20years. Given the rarity of this @entity1 , studies were not limited by design or number of reported @entity0 . RESULTS: UCS is biologically a de-differentiated @entity3 with its own pathogenesis and molecular profile. It commonly presents with extrauterine disease which can be identified by comprehensive surgical staging. Most UCS @entity0 are candidates for adjuvant chemotherapy. The role of radiation is less clear. Combination therapy, while commonly used, has not been studied in depth. The high recurrence rate and poor overall survival for UCS suggest an ongoing need for clinical trials for UCS specifically. CONCLUSIONS: UCS represents a distinct subtype of uterine @entity1 , and should be studied as such via focused clinical trials.

title: XXXX : A review of the literature.

answer: @entity4


abstract: OBJECTIVE: This study evaluates small-bore catheter thoracostomy combined with @entity5 sclerotherapy for palliative treatment of presumed @entity6 . SUBJECTS AND METHODS: Forty-seven consecutive @entity0 referred from the medical oncology department to the thoracic radiology section with known primary @entity1 and symptomatic @entity4 over a 2-year period were treated with small-bore pleural catheter drainage followed by @entity5 sclerotherapy. Of the 47 @entity0 , 20 (43%) died less than 30 days after sclerotherapy, one (2%) died without radiographic follow-up, and five (11%) were lost to follow-up. Twenty-one @entity0 formed the study group. Response to treatment was defined based on findings on follow-up chest radiographs obtained 30 days after sclerotherapy as complete (no reaccumulation of @entity4 ), partial (accumulation above postpleurodesis level but below that at presentation), or as a failure (reaccumulation to the amount seen at presentation). RESULTS: Seventeen (81%) evaluable @entity0 showed complete response to sclerotherapy, three (14%) showed a partial response, and one (5%) showed no response. All complete and partial responders were clinically improved with resolution of their shortness of breath. Therefore, 95% of evaluable @entity0 had clinically and radiographically successful treatment. Six @entity0 underwent sclerotherapy when their tube output was greater than 100 ml/24 hr. Five of the six had completely successful pleurodesis, and one failed to respond. Two (10%) of the 21 @entity0 had greater than 150 ml drainage in the 24 hr after initial @entity5 administration and were therefore given a second dose of intrapleural @entity5 . Both of these @entity0 subsequently had less than 150 ml drainage in an additional 24-hr observation period and went on to complete response. Complications included three @entity0 (14%) with mild discomfort at the chest tube site during drainage, one @entity0 (5%) with @entity2 during instillation of @entity5 , and one @entity0 (5%) with transient @entity3 (38.3 degrees C body temperature) one day after sclerotherapy. CONCLUSION: Small-bore catheter thoracostomy followed by @entity5 sclerotherapy successfully resolves symptomatic @entity4 in @entity0 with known primary @entity1 .

title: Palliative treatment of @entity6 : value of small-bore catheter thoracostomy and XXXX sclerotherapy.

answer: @entity5


abstract: OBJECTIVE: This study evaluates small-bore catheter thoracostomy combined with @entity5 sclerotherapy for palliative treatment of presumed @entity6 . SUBJECTS AND METHODS: Forty-seven consecutive @entity0 referred from the medical oncology department to the thoracic radiology section with known primary @entity1 and symptomatic @entity4 over a 2-year period were treated with small-bore pleural catheter drainage followed by @entity5 sclerotherapy. Of the 47 @entity0 , 20 (43%) died less than 30 days after sclerotherapy, one (2%) died without radiographic follow-up, and five (11%) were lost to follow-up. Twenty-one @entity0 formed the study group. Response to treatment was defined based on findings on follow-up chest radiographs obtained 30 days after sclerotherapy as complete (no reaccumulation of @entity4 ), partial (accumulation above postpleurodesis level but below that at presentation), or as a failure (reaccumulation to the amount seen at presentation). RESULTS: Seventeen (81%) evaluable @entity0 showed complete response to sclerotherapy, three (14%) showed a partial response, and one (5%) showed no response. All complete and partial responders were clinically improved with resolution of their shortness of breath. Therefore, 95% of evaluable @entity0 had clinically and radiographically successful treatment. Six @entity0 underwent sclerotherapy when their tube output was greater than 100 ml/24 hr. Five of the six had completely successful pleurodesis, and one failed to respond. Two (10%) of the 21 @entity0 had greater than 150 ml drainage in the 24 hr after initial @entity5 administration and were therefore given a second dose of intrapleural @entity5 . Both of these @entity0 subsequently had less than 150 ml drainage in an additional 24-hr observation period and went on to complete response. Complications included three @entity0 (14%) with mild discomfort at the chest tube site during drainage, one @entity0 (5%) with @entity2 during instillation of @entity5 , and one @entity0 (5%) with transient @entity3 (38.3 degrees C body temperature) one day after sclerotherapy. CONCLUSION: Small-bore catheter thoracostomy followed by @entity5 sclerotherapy successfully resolves symptomatic @entity4 in @entity0 with known primary @entity1 .

title: Palliative treatment of XXXX : value of small-bore catheter thoracostomy and @entity5 sclerotherapy.

answer: @entity6


abstract: BACKGROUND: Correction of @entity1 in males is a frequently performed aesthetic procedure. Various surgical options involving the removal of excess skin, fat, or glandular tissue have been described. However, poor aesthetic outcomes, including a flat or @entity2 pectoral area, limit the success of these techniques. OBJECTIVES: The authors sought to determine @entity0 satisfaction with the results of upper chest augmentation by direct intrapectoral fat injection in conjunction with surgical correction of @entity1 . METHODS: In this prospective study, 26 @entity0 underwent liposuction and glandular excision, glandular excision alone, or Benelli-type skin excision. All @entity0 received intramuscular fat injections in predetermined zones of the pectoralis major (PM). The mean volume of fat injected was 160 mL (range, 80-220 mL per breast) bilaterally. @entity0 were monitored for an average of 16 months (range, 8-24 months). RESULTS: @entity3 formation and consequent @entity2 was noted in 1 @entity0 and was corrected by secondary lipografting. Mean @entity0 satisfaction was rated as 8.4 on a scale of 1 (unsatisfactory) to 10 (highly satisfactory). CONCLUSIONS: Autologous intrapectoral fat injection performed simultaneously with @entity1 correction can produce a masculine appearance. The long-term viability of fat cells injected into the PM needs to be determined. LEVEL OF EVIDENCE: 4 Therapeutic.

title: Autologous fat injection into the pectoralis major as an adjunct to surgical correction of XXXX .

answer: @entity1


abstract: BACKGROUND AND PURPOSE: In order to assess @entity1 regression and outcomes, a volumetric analysis was conducted for cervical @entity1 @entity0 treated with magnetic resonance imaging (MRI)-based image-guided brachytherapy (IGBT). MATERIALS AND METHODS: Consecutive @entity0 with FIGO stage @entity4 -IVA cervical @entity1 receiving chemoradiation from 2007 to 2013 were identified, excluding @entity0 with perineal template-based interstitial brachytherapy or without undergoing MRI. A ring and tandem applicator  interstitial needles was used. T2-weighted imaging was completed following applicator insertion. Gross @entity1 volumes (GTVs) were retrospectively contoured: initial GTV (GTVPre-EBRT), GTV at first brachytherapy (GTVIGBT) and percent residual GTV at first brachytherapy (% GTVResidual). RESULTS: Eighty-four @entity0 were identified. With 20.8-month median follow-up, two-year estimates of local control (LC), disease-free survival (DFS) and @entity3 ( @entity3 ) were 91.3, 79.8, and 85.0%, respectively. Multivariate Cox regression revealed @entity2 (HR 5.88, p=0.03) and GTVIGBT (HR 1.17, p<0.01) as predictors for local failure. GTVIGBT>7.5cc was associated with inferior 2-year LC (75.0 vs. 96.6%, p<0.01), DFS (42.6 vs. 91.6%, p<0.01) and @entity3 (65.2 vs. 91.5%, p<0.01). No difference in mean @entity5 D90 EQD2 was seen between the groups (p=0.61). CONCLUSION: Aside from known benefits of IGBT, MRI-based planning allows for assessment of @entity1 regression and prognosticates @entity0 .

title: XXXX outcome prediction to high-dose rate brachytherapy using quantitative magnetic resonance imaging analysis of @entity1 response to external beam radiotherapy.

answer: @entity1


abstract: BACKGROUND AND PURPOSE: In order to assess @entity1 regression and outcomes, a volumetric analysis was conducted for cervical @entity1 @entity0 treated with magnetic resonance imaging (MRI)-based image-guided brachytherapy (IGBT). MATERIALS AND METHODS: Consecutive @entity0 with FIGO stage @entity4 -IVA cervical @entity1 receiving chemoradiation from 2007 to 2013 were identified, excluding @entity0 with perineal template-based interstitial brachytherapy or without undergoing MRI. A ring and tandem applicator  interstitial needles was used. T2-weighted imaging was completed following applicator insertion. Gross @entity1 volumes (GTVs) were retrospectively contoured: initial GTV (GTVPre-EBRT), GTV at first brachytherapy (GTVIGBT) and percent residual GTV at first brachytherapy (% GTVResidual). RESULTS: Eighty-four @entity0 were identified. With 20.8-month median follow-up, two-year estimates of local control (LC), disease-free survival (DFS) and @entity3 ( @entity3 ) were 91.3, 79.8, and 85.0%, respectively. Multivariate Cox regression revealed @entity2 (HR 5.88, p=0.03) and GTVIGBT (HR 1.17, p<0.01) as predictors for local failure. GTVIGBT>7.5cc was associated with inferior 2-year LC (75.0 vs. 96.6%, p<0.01), DFS (42.6 vs. 91.6%, p<0.01) and @entity3 (65.2 vs. 91.5%, p<0.01). No difference in mean @entity5 D90 EQD2 was seen between the groups (p=0.61). CONCLUSION: Aside from known benefits of IGBT, MRI-based planning allows for assessment of @entity1 regression and prognosticates @entity0 .

title: @entity1 outcome prediction to high-dose rate brachytherapy using quantitative magnetic resonance imaging analysis of XXXX response to external beam radiotherapy.

answer: @entity1


abstract: OBJECTIVE: To compare outcomes following totally transanal endorectal pull-through (TTERPT) versus pull-through with any form of laparoscopic assistance (LAPT) for @entity0 with uncomplicated @entity8 . DESIGN: Systematic review and meta-analysis. SETTING: Five hospitals with a paediatric surgical service. @entity0 : 405 @entity0 with uncomplicated @entity8 . INTERVENTIONS: TTERPT versus LAPT. PRIMARY AND SECONDARY OUTCOME MEASURES:                 <AbstractText Label="PRIMARY OUTCOMES" NlmCategory="METHODS">mortality, @entity1 , @entity3 , @entity6 , unplanned laparotomy or stoma formation, and @entity10 . SECONDARY OUTCOMES: @entity4 requiring transfusion of blood products, @entity5 formation, @entity7 , intestinal ischaemia, enteric @entity2 formation, @entity3 or retention, impotency and duration of procedure. RESULTS: Five eligible studies comprising 405 @entity0 were identified from 2107 studies. All studies were retrospective case series, with variability in outcome assessment quality and length of follow-up. Operative duration was 50.29   min shorter with TTERPT (95% CI 39.83 to 60.74, p<0.00001). There were no significant differences identified between TTERPT and LAPT for incidence of @entity1 (OR=0.78, 95% CI 0.44 to 1.38, p=0.39), @entity3 (OR=0.44, 95% CI 0.09 to 2.20, p=0.32) or @entity6 (OR=0.84, 95% CI 0.32 to 2.17, p=0.71). CONCLUSIONS: This meta-analysis did not find any evidence to suggest a higher rate of @entity9 , @entity3 or @entity6 following TTERPT compared with LAPT. Further long-term comparative studies and multicentre data pooling are needed to determine whether a purely transanal approach offers any advantages over a laparoscopically assisted approach to rectosigmoid @entity8 . TRIAL REGISTRATION NUMBER: PROSPERO registry- CRD42013005698.

title: Laparoscopic assistance for primary transanal pull-through in XXXX : a systematic review and meta-analysis.

answer: @entity8


abstract: BACKGROUND:    The targets and mechanisms of @entity0 immunity to @entity1 are poorly understood, which poses a major barrier to @entity1 vaccine development. Antibodies play a key role in @entity0 immunity and may act by inhibiting receptor-binding functions of key merozoite invasion ligands. Antibodies to the major invasion ligand and vaccine candidate, erythrocyte-binding antigen 175 (EBA-175), have been linked with protection, but how these antibodies function has not been established. METHODS:    We developed 2 new assays that quantify the ability of antibodies to inhibit binding of EBA-175 to its @entity2 , glycophorin A, using either native or recombinant EBA-175. Binding-inhibitory antibodies were evaluated in a longitudinal cohort study of Papua New Guinean @entity0 and related to risk of @entity1 , age, infection status, and markers of parasite exposure. RESULTS:    Binding-inhibition assays (BIAs) were reproducible, and the 2 assays had a high level of agreement. Inhibitory antibodies were common among @entity0 , acquired in association with markers of increasing parasite exposure, and high in those @entity0 with active infection. Inhibitory antibodies correlated with total immunoglobulin G levels to the EBA-175 binding domain (region II). Importantly, binding-inhibitory antibodies were significantly associated with protection from symptomatic @entity1 when measured using either BIA. CONCLUSIONS:    Findings suggest that naturally acquired binding-inhibitory antibodies are an important functional mechanism that contributes to protection against @entity1 and further supports the potential of EBA-175 as a vaccine candidate. Identifying vaccines and approaches that induce potent binding-inhibitory antibodies may be a valuable strategy in the development of highly efficacious @entity1 vaccines.

title: Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection Against Plasmodium falciparum Malaria in XXXX .

answer: @entity0


abstract: @entity5 ( @entity5 ) are rare, but potentially devastating @entity1 , with @entity3 fungoides and S  zary Syndrome being the most common. In our previous study, we identified and described regions of geographic clustering of @entity4 cases in Texas by analyzing ~1990 @entity0 using two distinct @entity1 registries. In the current work, we describe in detail demographic patterns for this @entity1 in our study population and apply logistic regression models to analyze the incidence of @entity4 by sex, race, age, and clinical stage at the time of diagnosis. Furthermore, using Fisher's exact test, we analyze changes in incidence over time in the identified Houston communities with unusually high @entity4 incidence. While @entity4 primarily affects Caucasian individuals >55  years old, we confirm that it presents at a younger age and with more @entity2 stages in African-American and Hispanic individuals. Also, we demonstrate a significant increase in @entity4 incidence over time in the identified communities. Spring, Katy, and Houston Memorial areas had high baseline rates. Furthermore, a statistically significant disease surge was observed in these areas after ~2005. This report supplements our initial study documenting the existence of geographic clustering of @entity4 cases in Texas and in greater detail describes demographic trends for our @entity0 population. The observed surge in @entity4 incidence in the three identified communities further argues that this @entity1 may be triggered by one or more external etiologic agents.

title: Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different XXXX registries.

answer: @entity1


abstract: UNASSIGNED: Venous saline infusions in an arterially occluded forearm evokes reflex increases in muscle sympathetic nerve activity (MSNA) and blood pressure (BP). We hypothesized that the application of suction to the @entity0 limbs would activate this @entity1 reflex and raise sympathetic outflow. We placed airtight pressure tanks and applied 100 mmHg negative pressure to an arterially occluded limb (occlusion and suction, O_S) to induce tissue deformation without fluid translocation. BP, heart rate (HR), and MSNA were assessed in 19 healthy subjects during 2 minutes of arm or leg O_S. Occlusion without suction served as a control. During a separate visit, saline (5% forearm volume) was infused into veins of the arterially occluded arm (N = 13). The O_S increased limb circumference, MSNA burst rate (arm:   6.7    0.7; leg:   6.8    0.7 bursts/min) and total activity (arm:   199    14; leg:   172    22 units/min) and BP (arm:   4.3    0.3; leg:   9.4    1.4 mmHg) from the baseline. The MSNA and BP responses during arm O_S correlated with those during leg O_S. Occlusion alone had no effect on MSNA and BP. MSNA (R = 0.607) responses during arm O_S correlated with those evoked by the saline infusion into the arm. These correlations suggest that sympathetic activation during limb O_S is likely, at least partially, to be evoked via the @entity1 reflex. These data suggest that suction of an occluded limb evokes sympathetic activation, and that the limb @entity1 reflex exists in arms and legs of normal @entity0 .

title: Limb suction evoked during arterial occlusion causes systemic sympathetic activity in XXXX .

answer: @entity0


abstract: INTRODUCTION: The early hepatic @entity4 (HVOO) is a rare but serious complication after liver transplantation, which may result in graft loss. We report a case of early HVOO after living donor liver transplantation, which was managed by ectopic placement of foley catheter. PRESENTATION: A 51 years old male @entity0 with @entity5 received a right hemi-liver graft. On the first postoperative day the @entity0 developed @entity1 . Doppler ultrasound (US) showed absence of blood flow in the right hepatic vein without @entity2 . The decision was to re-explore the @entity0 , which showed torsion of the graft upward and to the right side causing HVOO. This was managed by ectopic placement of a foley catheter between the graft and the diaphragm and the chest wall. Gradual deflation of the catheter was gradually done guided by Doppler US and the @entity0 was discharged without complications. DISCUSSION: Mechanical HVOO results from kinking or twisting of the @entity3 due to anatomical mismatch between the graft and the recipient abdomen. It should be managed surgically by repositioning of the graft or redo of @entity3 . Several ideas had been suggested for repositioning and fixation of the graft by the use of @entity6 , tissue expanders, and surgical glove expander. CONCLUSION: We report the use of foley catheter to temporary fix the graft and correct the HVOO. It is a simple and safe way, and could be easily monitored and removed under Doppler US without any complications.

title: XXXX after living donor liver transplantation managed with ectopic placement of a foley catheter: A case report.

answer: @entity4


abstract: UNASSIGNED: First @entity3 are uncommon lesions that often present as @entity1 . They have high recurrence rates, due in part to scarring secondary to prior @entity1 and their management. These lesions have a close relationship with the facial nerve, and most authors recommend its identification and dissection because of this relationship. Nonetheless, @entity2 has been reported in up to 15% of cases. We describe a novel technique for the management of first @entity3 . Such lesions that presented in an infra- or postauricular location were approached via an incision through the cartilage of the pinna, between the tragus and antitragus. This technique affords direct access to the lesion without the need for facial nerve dissection. Six @entity0 were treated. Five had prior surgery, including 3 with previous attempts at excision. There were no complications. The median follow-up was 35 months. One @entity0 developed a recurrence.

title: Management of First XXXX via a Cartilage-Splitting Technique.

answer: @entity3


abstract: PURPOSE: The purpose of this study is to report the outcomes of an algorithm-based multidisciplinary treatment approach to @entity2 . METHODS: This study is a retrospective review of a prospectively collected database at a tertiary center of all consecutive @entity0 treated between 2003 and 2013. RESULTS: Thirty males (mean age 63  years) were reviewed. @entity1 treatment was the most common @entity2 etiology (97  %). Urinary drainage consisted of urethral catheter in all @entity0 and suprapubic catheter in 14 (47  %). The rate of fecal diversion was 67  %. During a mean follow-up of 72  months, healing rate was 90  % and recurrence rate 0  %. Spontaneous healing was achieved in 14 @entity0 (47  %): 8 (27  %) without fecal diversion and 6 (20  %) following fecal diversion. Thirteen @entity0 (43  %) required definitive intervention. The majority of operated @entity0 underwent transanal or transperineal flap (endorectal, dartos, or gracilis) successfully. Only 2 @entity0 (7  %) required an abdominal approach (positive oncologic margins or non-functioning bladder). Fifteen out of the 20 @entity0 (75  %) who underwent fecal diversion had stoma closure with an overall permanent stoma rate of 17  %. Long-term urinary incontinence was noted in 11 @entity0 (37  %). Six @entity0 (20  %) required permanent urinary diversion or drainage catheters. CONCLUSIONS: Algorithm-based treatment approach for @entity2 is useful in the management of this rare condition. Selective fecal diversion is possible, and majority of @entity0 who require definitive intervention can be treated with a transanal or transperineal approach. The rate of permanent stoma is low, but long-term urinary dysfunction is frequent.

title: Algorithm-based multidisciplinary treatment approach for XXXX .

answer: @entity2


abstract: @entity7 (HT) is the most prominent phenolic compound of virgin olive oil and due to its scientifically validated biological activities it is entering to the market as a potentially useful supplement for @entity3 prevention. The aim of the present study was to investigate the relationship between the HT dose intake and its tissue uptake in @entity2 , and thus, providing complementary information in relation to the target-dose relationship. @entity2 were given a refined olive oil enriched with HT at different doses (1, 10, and 100 mg/kg) and they were sacrificed after 5 h to ensure the cell tissue uptake of HT and its metabolites. Plasma samples and different organs as liver, kidney, heart and brain were obtained, and HT metabolites were analyzed by UPLC-MS/MS. The results showed that HT and its metabolites could be accumulated in a dose-dependent manner basically in the liver, kidney, and brain and were detected in these tissues even at nutritionally relevant @entity0 doses. The detection of free @entity4 was noteworthy. To date, this appears to be the only biologically active form, and thus, it provides relevant information for optimizing the potential applications of HT to prevent certain hepatic and @entity1 . In recent years, HT and its derivatives have led to a great interest from the virgin olive oil producers and manufacturers of nutraceutical supplements. The increasing interest in HT is mainly due to the European Food Safety Agency (EFSA) Panel on Dietetic Products, Nutrition, and @entity5 (NDA) scientific opinion that established a cause-and-effect relationship between the consumption of olive oil @entity6 and protection of LDL particles from oxidative damage . Based on this positive opinion, the health claim "Olive oil @entity6 contribute to the protection of blood lipids from oxidative stress" was included in the list of health claims , being the only authorized health claim in the European Union regarding @entity6 and health.

title: Dose effect on the uptake and accumulation of XXXX and its metabolites in target tissues in @entity2 .

answer: @entity7


abstract: @entity7 (HT) is the most prominent phenolic compound of virgin olive oil and due to its scientifically validated biological activities it is entering to the market as a potentially useful supplement for @entity3 prevention. The aim of the present study was to investigate the relationship between the HT dose intake and its tissue uptake in @entity2 , and thus, providing complementary information in relation to the target-dose relationship. @entity2 were given a refined olive oil enriched with HT at different doses (1, 10, and 100 mg/kg) and they were sacrificed after 5 h to ensure the cell tissue uptake of HT and its metabolites. Plasma samples and different organs as liver, kidney, heart and brain were obtained, and HT metabolites were analyzed by UPLC-MS/MS. The results showed that HT and its metabolites could be accumulated in a dose-dependent manner basically in the liver, kidney, and brain and were detected in these tissues even at nutritionally relevant @entity0 doses. The detection of free @entity4 was noteworthy. To date, this appears to be the only biologically active form, and thus, it provides relevant information for optimizing the potential applications of HT to prevent certain hepatic and @entity1 . In recent years, HT and its derivatives have led to a great interest from the virgin olive oil producers and manufacturers of nutraceutical supplements. The increasing interest in HT is mainly due to the European Food Safety Agency (EFSA) Panel on Dietetic Products, Nutrition, and @entity5 (NDA) scientific opinion that established a cause-and-effect relationship between the consumption of olive oil @entity6 and protection of LDL particles from oxidative damage . Based on this positive opinion, the health claim "Olive oil @entity6 contribute to the protection of blood lipids from oxidative stress" was included in the list of health claims , being the only authorized health claim in the European Union regarding @entity6 and health.

title: Dose effect on the uptake and accumulation of @entity7 and its metabolites in target tissues in XXXX .

answer: @entity2


abstract: UNASSIGNED: The current study reports the case of a @entity2 treated with modified @entity7 ( @entity7 ) radiotherapy. A 45-year-old female presented to the emergency department complaining of left @entity6 and @entity4 . A computed tomography scan detected a retroperitoneal @entity2 of 12*16*16 cm, and a biopsy revealed a poorly-differentiated @entity5 . The @entity0 was diagnosed with a large @entity5 originating from the left ureter, with no distant @entity1 . Due to the @entity0 's poor physical condition, surgery was not recommended, and the @entity0 was referred to the Department of Radiation Oncology (Yamagata University Hospital, Yamagata, Japan). Modified @entity7 radiotherapy was administered following the acquisition of written consent from the @entity0 . The total irradiation dose to the center of the @entity2 and to the surrounding healthy tissue was    96 Gy/33 fractions and <60 Gy/33 fractions, respectively. At the end of the radiotherapeutic course, the @entity2 volume was reduced by >= 80%, and the @entity3 was surgically resected. As a result of the resection, a complete pathological response was confirmed; the @entity0 has been recurrence-free for >3 years with no complications. Modified @entity7 radiotherapy may be safely administered, with favorable outcomes. Complete recovery can be achieved with this technique, even in a @entity0 with a large radioresistant @entity2 .

title: Modified XXXX radiotherapy for large retroperitoneal @entity2 : A case report.

answer: @entity7


abstract: UNASSIGNED: The current study reports the case of a @entity2 treated with modified @entity7 ( @entity7 ) radiotherapy. A 45-year-old female presented to the emergency department complaining of left @entity6 and @entity4 . A computed tomography scan detected a retroperitoneal @entity2 of 12*16*16 cm, and a biopsy revealed a poorly-differentiated @entity5 . The @entity0 was diagnosed with a large @entity5 originating from the left ureter, with no distant @entity1 . Due to the @entity0 's poor physical condition, surgery was not recommended, and the @entity0 was referred to the Department of Radiation Oncology (Yamagata University Hospital, Yamagata, Japan). Modified @entity7 radiotherapy was administered following the acquisition of written consent from the @entity0 . The total irradiation dose to the center of the @entity2 and to the surrounding healthy tissue was    96 Gy/33 fractions and <60 Gy/33 fractions, respectively. At the end of the radiotherapeutic course, the @entity2 volume was reduced by >= 80%, and the @entity3 was surgically resected. As a result of the resection, a complete pathological response was confirmed; the @entity0 has been recurrence-free for >3 years with no complications. Modified @entity7 radiotherapy may be safely administered, with favorable outcomes. Complete recovery can be achieved with this technique, even in a @entity0 with a large radioresistant @entity2 .

title: Modified @entity7 radiotherapy for large retroperitoneal XXXX : A case report.

answer: @entity2


abstract: The influence of the immunosuppressive antibiotic agent @entity7 ( @entity8 ) on macrophages and autoreactive T helper lymphocytes from Lewis @entity0 was analysed in vitro and in vivo. @entity8 did not inhibit antigen- or mitogen-induced proliferation of @entity4 helper cell lines in vitro. However, the presence of @entity8 during in vitro activation of the T cells strongly suppressed or completely abrogated their capacity to induce @entity2 (EAE) or @entity5 (EAN) after adoptive transfer to naive @entity0 , although expression of activation markers or adhesion molecules on the T line blasts was not down-regulated by @entity8 . Like activation-induced T cell proliferation, @entity6 -dependent growth of @entity10 + T line cells was not affected by @entity8 . Preincubation of @entity10 + T line cells in @entity8 during @entity6 -driven proliferation for 48 h, however, inhibited the subsequent antigen- but not mitogen-induced activation of these T cells, although neither density of T cell receptors nor other surface molecules involved in antigen recognition were lowered on the cells exposed to @entity8 . Similar to its effect in vitro, in vivo administration of @entity8 for 10 days even at a concentration with cumulative @entity1 did not suppress in vitro proliferation of spleen cells induced by mitogen or a mitogenic combination of anti- @entity9 antibodies. Furthermore, spleen cell and peripheral blood lymphocyte (PBL) surface antigens, particularly MHC molecules, were not altered by long-term treatment with @entity8 for 30 days. While there was a slight reduction in the number of polymorphonuclear cells in both populations, the proportion of the different leucocyte subpopulations remained unchanged. In contrast to the strong functional impact of @entity8 on autoreactive T helper cells, the drug did not inhibit the oxidative burst of macrophages or their MHC antigen expression. This study demonstrates a clear inhibitory effect of @entity8 on @entity10 + T lymphocytes, but not macrophages. It provides an explanation for recent observations of a strong immunosuppressive in vivo effect of @entity8 on transplantation rejection and experimental @entity3 , despite a normal mitogen response of T cells exposed to @entity8 in vivo and in vitro.

title: Impact of XXXX on effector cells in experimental autoimmune diseases of the nervous system in the Lewis @entity0 .

answer: @entity7


abstract: The influence of the immunosuppressive antibiotic agent @entity7 ( @entity8 ) on macrophages and autoreactive T helper lymphocytes from Lewis @entity0 was analysed in vitro and in vivo. @entity8 did not inhibit antigen- or mitogen-induced proliferation of @entity4 helper cell lines in vitro. However, the presence of @entity8 during in vitro activation of the T cells strongly suppressed or completely abrogated their capacity to induce @entity2 (EAE) or @entity5 (EAN) after adoptive transfer to naive @entity0 , although expression of activation markers or adhesion molecules on the T line blasts was not down-regulated by @entity8 . Like activation-induced T cell proliferation, @entity6 -dependent growth of @entity10 + T line cells was not affected by @entity8 . Preincubation of @entity10 + T line cells in @entity8 during @entity6 -driven proliferation for 48 h, however, inhibited the subsequent antigen- but not mitogen-induced activation of these T cells, although neither density of T cell receptors nor other surface molecules involved in antigen recognition were lowered on the cells exposed to @entity8 . Similar to its effect in vitro, in vivo administration of @entity8 for 10 days even at a concentration with cumulative @entity1 did not suppress in vitro proliferation of spleen cells induced by mitogen or a mitogenic combination of anti- @entity9 antibodies. Furthermore, spleen cell and peripheral blood lymphocyte (PBL) surface antigens, particularly MHC molecules, were not altered by long-term treatment with @entity8 for 30 days. While there was a slight reduction in the number of polymorphonuclear cells in both populations, the proportion of the different leucocyte subpopulations remained unchanged. In contrast to the strong functional impact of @entity8 on autoreactive T helper cells, the drug did not inhibit the oxidative burst of macrophages or their MHC antigen expression. This study demonstrates a clear inhibitory effect of @entity8 on @entity10 + T lymphocytes, but not macrophages. It provides an explanation for recent observations of a strong immunosuppressive in vivo effect of @entity8 on transplantation rejection and experimental @entity3 , despite a normal mitogen response of T cells exposed to @entity8 in vivo and in vitro.

title: Impact of @entity7 on effector cells in experimental autoimmune diseases of the nervous system in the Lewis XXXX .

answer: @entity0


abstract: BACKGROUND: @entity7 , characterized by Libman-Sacks @entity2 , is common in @entity0 with @entity7 and is commonly complicated with @entity6 . Thus, accurate detection of Libman-Sacks @entity2 may lead to early therapy and prevention of their associated complications. Although two-dimensional (2D) transesophageal echocardiography (TEE) has high diagnostic value for detection of Libman-Sacks @entity2 , three-dimensional (3D) TEE may allow improved detection, characterization, and clinical correlations of Libman-Sacks @entity2 . METHODS: Twenty-nine @entity0 with @entity7 (27 @entity0 ; mean age, 34      12  years) prospectively underwent 40 paired 3D and 2D transesophageal echocardiographic studies and assessment of @entity3 manifested as @entity1 , @entity4 , or focal @entity8 on magnetic resonance imaging. Initial and repeat studies in @entity0 were intermixed in a blinded manner with paired studies from healthy controls, deidentified, coded, and independently interpreted by experienced observers unaware of @entity0 ' clinical and imaging data. RESULTS: The results of 3D TEE compared with 2D TEE were more often positive for mitral or @entity5 , and 3D TEE detected more @entity2 per study and determined larger sizes of @entity2 (P   <=  .03 for all). Also, 3D TEE detected more @entity2 on the anterior mitral leaflet, anterolateral and posteromedial scallops, and ventricular side or both atrial and ventricular sides of the leaflets (P  <  .05 for all). In addition, 3D TEE detected more @entity2 on the aortic valve left and noncoronary cusps, coronary cusps' tips and margins, and aortic side or both aortic and ventricular sides of the cusps (P   <=  .01 for all). Furthermore, 3D TEE more often detected associated mitral or aortic valve commissural fusion (P  = .002). Finally, 3D TEE detected more @entity2 in @entity0 with @entity3 (P  = .01). CONCLUSIONS: Three-dimensional TEE provides clinically relevant additive information that complements 2D TEE for the detection, characterization, and association with @entity3 of @entity7 .

title: XXXX : Detection, Characterization, and Clinical Correlates by Three-Dimensional Transesophageal Echocardiography.

answer: @entity7


abstract: BACKGROUND: Public awareness campaigns for @entity1 are used to alert the UK population to symptoms which, if experienced, should be discussed with their general practitioner (GP). More timely diagnosis of @entity1 is assumed possible if @entity0 with the appropriate symptoms present to GPs and GPs recognise the need to act on these symptoms. OBJECTIVE: To investigate @entity2 perceptions and experiences of public awareness campaigns for @entity1 . METHODS: Semi-structured interviews with 55 GPs from practices in the North and North East of England and Greater London. Interviews were recorded and transcribed verbatim. Repeated reading of GP transcripts engendered thematic analysis and co-coding ensured legitimacy of findings. RESULTS: @entity0 supported the underpinning ethos of public health campaigns and articulated a commitment to engaging with @entity0 with respect to @entity1 warning signs and symptoms despite the common perception that public awareness campaigns increased numbers of consultations. Tensions were evident with regard to increased demands on GP time and primary care resources during a period of major upheaval within the NHS. Concern was raised that some @entity0 remain outwith the reach of campaign messages. The complexity of addressing how public health messages compete with other issues in @entity0 's lives was identified as challenging. CONCLUSIONS: General practitioners provided insight into why some members of the general public do not engage with public health messages. Public health/primary care interaction that incorporates @entity2 knowledge of their @entity0 populations could advance the search for solutions to a more robust approach to earlier @entity1 recognition and referral in primary care.

title: @entity2 perceptions and experiences of public awareness campaigns for XXXX : a qualitative enquiry.

answer: @entity1


abstract: BACKGROUND: Public awareness campaigns for @entity1 are used to alert the UK population to symptoms which, if experienced, should be discussed with their general practitioner (GP). More timely diagnosis of @entity1 is assumed possible if @entity0 with the appropriate symptoms present to GPs and GPs recognise the need to act on these symptoms. OBJECTIVE: To investigate @entity2 perceptions and experiences of public awareness campaigns for @entity1 . METHODS: Semi-structured interviews with 55 GPs from practices in the North and North East of England and Greater London. Interviews were recorded and transcribed verbatim. Repeated reading of GP transcripts engendered thematic analysis and co-coding ensured legitimacy of findings. RESULTS: @entity0 supported the underpinning ethos of public health campaigns and articulated a commitment to engaging with @entity0 with respect to @entity1 warning signs and symptoms despite the common perception that public awareness campaigns increased numbers of consultations. Tensions were evident with regard to increased demands on GP time and primary care resources during a period of major upheaval within the NHS. Concern was raised that some @entity0 remain outwith the reach of campaign messages. The complexity of addressing how public health messages compete with other issues in @entity0 's lives was identified as challenging. CONCLUSIONS: General practitioners provided insight into why some members of the general public do not engage with public health messages. Public health/primary care interaction that incorporates @entity2 knowledge of their @entity0 populations could advance the search for solutions to a more robust approach to earlier @entity1 recognition and referral in primary care.

title: XXXX perceptions and experiences of public awareness campaigns for @entity1 : a qualitative enquiry.

answer: @entity2


abstract: BACKGROUND: Less than 50% of @entity0 with @entity1 ( @entity1 ) reach symptomatic remission with their initial antidepressant medication (ADM). There are currently no objective measures with which to reliably predict which individuals will achieve remission to ADMs. METHODS: 157 @entity0 with @entity1 from the International Study to Predict Optimized Treatment in @entity1 (iSPOT-D) underwent baseline MRIs and completed eight weeks of treatment with @entity2 , @entity4 or @entity3 -ER. A score at week 8 of 7 or less on the 17 item Hamilton Rating Scale for @entity1 defined remission. Receiver Operator Characteristics (ROC) analysis using the first 50% @entity0 was performed to define decision trees of baseline MRI volumetric and connectivity (fractional anisotropy) measures that differentiated non-remitters from remitters with maximal sensitivity and specificity. These decision trees were tested for replication in the remaining @entity0 . FINDINGS: Overall, 35% of all @entity0 achieved remission. ROC analyses identified two decision trees that predicted a high probability of non-remission and that were replicated: 1. Left middle frontal volume  <  14      8  mL _ right angular gyrus volume  >  6      3  mL identified 55% of non-remitters with 85% accuracy; and 2. Fractional anisotropy values in the left cingulum bundle  <  0      63, right superior fronto-occipital fasciculus  <  0      54 and right superior longitudinal fasciculus  <  0      50 identified 15% of the non-remitters with 84% accuracy. All @entity0 who met criteria for both decision trees were correctly identified as non-remitters. INTERPRETATION: Pretreatment MRI measures seem to reliably identify a subset of @entity0 who do not remit with a first step medication that includes one of these commonly used medications. Findings are consistent with a neuroanatomical basis for non-remission in @entity1 @entity0 . FUNDING: Brain Resource Ltd is the sponsor for the iSPOT-D study (NCT00693849).

title: Magnetic Resonance Imaging Measures of Brain Structure to Predict Antidepressant Treatment Outcome in XXXX .

answer: @entity1


abstract: OBJECTIVES: To evaluate the efficiency of mastoid antral @entity2 (MAVT) treatment in recurrent/ @entity1 media with effusion (OME). METHODS: 20 OME @entity0 who were unsuccessfully treated with @entity2 ( @entity2 ) at least twice, who consented to MAVT and who were followed up at least three years were included in the study group. Control group comprised 10 @entity0 who had the same characteristics and refused to undergo MAVT and underwent @entity2 placement again. Pre-operative and post-operative otomicroscopic, hearing tests, and CT findings were compared between the groups statistically. RESULTS: MAVT was placed into 24 ears of 20 @entity0 . In the control group, @entity2 was placed in 13 ears of 10 @entity0 . Postoperatively, in the study group, one tympanic membrane with adhesion and nine membranes with retraction returned to their anatomic positions after MAVT. In the control group, 2 retracted tympanic membranes returned to normal position. There was significant difference between groups in terms of mastoid aeration (P = 0.006). Post-operative pure tone threshold values and mastoid aeration findings were statistically different from preoperative conditions. CONCLUSION: This preliminary study demonstrates that MAVT may be effective in the surgical treatment of recurrent/chronic OME. However, further studies with larger @entity0 series should be carried out.

title: Mastoid antral XXXX ; new treatment modality for reccurent otitis media with effusion and its long term results.

answer: @entity2


abstract: Despite the steadily increasing number of @entity0 suffering from @entity6 of the oropharyngeal region, little is known about the molecular steps involved in the induction of these @entity3 . The aim of this study was to determine the incidence and type of @entity5 mutations in @entity6 . Five of 38 @entity0 had lymph node @entity2 , three @entity0 had multiple primary @entity4 and two @entity0 presented with multiple primary @entity3 and lymph node @entity2 . Exons 5 through 8 of the @entity5 gene were screened by single-strand conformation polymorphism analysis followed by direct DNA sequencing. A total of 16 @entity3 (42%) contained point mutations scattered throughout exons 5 to 8. Most mutations (56%) were transitions, predominantly G-->A. G-->T mutations prevailed among the transversions that have also been found in smoking-related @entity1 . One @entity4 showed a mutation which was retained in a lymph node @entity2 . The status of @entity5 differed in primary @entity4 of @entity0 with @entity3 indicating an independent generation of these @entity3 . The frequent occurrence of @entity5 mutations in @entity4 supports the view that this gene plays a role in initiation or progression of the malignant phenotype.

title: XXXX mutations in @entity4 : a comparison of solitary and multiple primary @entity3 and lymph node @entity2 .

answer: @entity5


abstract: Despite the steadily increasing number of @entity0 suffering from @entity6 of the oropharyngeal region, little is known about the molecular steps involved in the induction of these @entity3 . The aim of this study was to determine the incidence and type of @entity5 mutations in @entity6 . Five of 38 @entity0 had lymph node @entity2 , three @entity0 had multiple primary @entity4 and two @entity0 presented with multiple primary @entity3 and lymph node @entity2 . Exons 5 through 8 of the @entity5 gene were screened by single-strand conformation polymorphism analysis followed by direct DNA sequencing. A total of 16 @entity3 (42%) contained point mutations scattered throughout exons 5 to 8. Most mutations (56%) were transitions, predominantly G-->A. G-->T mutations prevailed among the transversions that have also been found in smoking-related @entity1 . One @entity4 showed a mutation which was retained in a lymph node @entity2 . The status of @entity5 differed in primary @entity4 of @entity0 with @entity3 indicating an independent generation of these @entity3 . The frequent occurrence of @entity5 mutations in @entity4 supports the view that this gene plays a role in initiation or progression of the malignant phenotype.

title: @entity5 mutations in XXXX : a comparison of solitary and multiple primary @entity3 and lymph node @entity2 .

answer: @entity4


abstract: Despite the steadily increasing number of @entity0 suffering from @entity6 of the oropharyngeal region, little is known about the molecular steps involved in the induction of these @entity3 . The aim of this study was to determine the incidence and type of @entity5 mutations in @entity6 . Five of 38 @entity0 had lymph node @entity2 , three @entity0 had multiple primary @entity4 and two @entity0 presented with multiple primary @entity3 and lymph node @entity2 . Exons 5 through 8 of the @entity5 gene were screened by single-strand conformation polymorphism analysis followed by direct DNA sequencing. A total of 16 @entity3 (42%) contained point mutations scattered throughout exons 5 to 8. Most mutations (56%) were transitions, predominantly G-->A. G-->T mutations prevailed among the transversions that have also been found in smoking-related @entity1 . One @entity4 showed a mutation which was retained in a lymph node @entity2 . The status of @entity5 differed in primary @entity4 of @entity0 with @entity3 indicating an independent generation of these @entity3 . The frequent occurrence of @entity5 mutations in @entity4 supports the view that this gene plays a role in initiation or progression of the malignant phenotype.

title: @entity5 mutations in @entity4 : a comparison of solitary and multiple primary @entity3 and lymph node XXXX .

answer: @entity2


abstract: Despite the steadily increasing number of @entity0 suffering from @entity6 of the oropharyngeal region, little is known about the molecular steps involved in the induction of these @entity3 . The aim of this study was to determine the incidence and type of @entity5 mutations in @entity6 . Five of 38 @entity0 had lymph node @entity2 , three @entity0 had multiple primary @entity4 and two @entity0 presented with multiple primary @entity3 and lymph node @entity2 . Exons 5 through 8 of the @entity5 gene were screened by single-strand conformation polymorphism analysis followed by direct DNA sequencing. A total of 16 @entity3 (42%) contained point mutations scattered throughout exons 5 to 8. Most mutations (56%) were transitions, predominantly G-->A. G-->T mutations prevailed among the transversions that have also been found in smoking-related @entity1 . One @entity4 showed a mutation which was retained in a lymph node @entity2 . The status of @entity5 differed in primary @entity4 of @entity0 with @entity3 indicating an independent generation of these @entity3 . The frequent occurrence of @entity5 mutations in @entity4 supports the view that this gene plays a role in initiation or progression of the malignant phenotype.

title: @entity5 mutations in @entity4 : a comparison of solitary and multiple primary XXXX and lymph node @entity2 .

answer: @entity3


abstract: @entity4 is characterized by distortion of @entity3 , @entity1 of hepatocytes and regenerative nodules formation leading to @entity2 . Various types of cell sources have been used for the management and treatment of decompensated @entity4 . Knowledge of stem cells has offered a new dimension for regenerative therapy and has been considered as one of the potential adjuvant treatment modality in @entity0 with @entity5 ( @entity5 ). @entity0 fetal hepatic progenitor cells are less immunogenic than adult ones. They are highly propagative and challenging to cryopreservation. In our earlier studies we have demonstrated that fetuses at 10-18 wk of gestation age contain a large number of actively dividing hepatic stem and progenitor cells which possess bi-potent nature having potential to differentiate into bile duct cells and mature hepatocytes. Hepatic stem cell therapy for the treatment of @entity5 is in their early stage of the translation. The emerging technology of decellularization and recellularization might offer a significant platform for developing bioengineered personalized livers to come over the scarcity of desired number of donor organs for the treatment of @entity5 . Despite these significant advancements long-term tracking of stem cells in @entity0 is the most important subject nowadays in order to answer several unsettles issues regarding the route of delivery, the choice of stem cell type(s), the cell number and the time-point of cell delivery for the treatment in a chronic setting. Answering to these questions will further contribute to the development of safer, noninvasive, and repeatable imaging modalities that could discover better cell therapeutic approaches from bench to bed-side. Combinatorial approach of decellularization and nanotechnology could pave a way towards the better understanding in determination of cell fate post-transplantation.

title: Hepatic stem cells: A viable approach for the treatment of XXXX .

answer: @entity4


abstract: BACKGROUND: Mesenchymal stem cells (MSCs) are considered an attractive approach for gene or drug delivery in @entity1 therapy. Thus, in this study, the ability of @entity0 bone marrow-derived MSCs expressing the cytosine deaminase/5-fluorocytosine prodrug ( @entity5 /5-FC MSCs) to target the @entity0 @entity4 cell line Cal72 was evaluated. METHODS: The stable @entity5 /5FC MSC cell line was established by transfection of pEGFP containing the cytosine deaminase gene into MSCs with G418 selection. The anti- @entity1 effect was verified by a bystander effect assay in vitro and co-injection of Cal72 and @entity5 /5FC MSCs in @entity1 -bearing @entity2 . RESULTS: The therapeutic @entity5 /5-FC MSCs retained the characteristics of multipotent cells such as differentiation into adipocytes/osteocytes and expression of mesenchymal markers ( @entity7 and @entity6 ), and showed migration toward @entity0 cells to a greater extent than the native MSCs. The bystander effect assay showed that the @entity5 /5-FC MSCs significantly augmented Cal72 @entity3 in direct co-culture and in the presence of 5-FC through the application of conditioned medium. In @entity4 -bearing @entity2 , the @entity5 /5-FC MSCs inhibited @entity1 growth when compared with control @entity2 subcutaneously injected with only @entity0 cells. CONCLUSIONS: Taken together, these findings suggest that @entity5 /5-FC MSCs may be suitable for targeting @entity0 @entity4 . This article is protected by copyright. All rights reserved.

title: Targeted inhibition of XXXX growth by bone marrow-derived mesenchymal stem cells expressing cytosine deaminase/5-fluorocytosine in @entity1 -bearing @entity2 .

answer: @entity4


abstract: BACKGROUND: Mesenchymal stem cells (MSCs) are considered an attractive approach for gene or drug delivery in @entity1 therapy. Thus, in this study, the ability of @entity0 bone marrow-derived MSCs expressing the cytosine deaminase/5-fluorocytosine prodrug ( @entity5 /5-FC MSCs) to target the @entity0 @entity4 cell line Cal72 was evaluated. METHODS: The stable @entity5 /5FC MSC cell line was established by transfection of pEGFP containing the cytosine deaminase gene into MSCs with G418 selection. The anti- @entity1 effect was verified by a bystander effect assay in vitro and co-injection of Cal72 and @entity5 /5FC MSCs in @entity1 -bearing @entity2 . RESULTS: The therapeutic @entity5 /5-FC MSCs retained the characteristics of multipotent cells such as differentiation into adipocytes/osteocytes and expression of mesenchymal markers ( @entity7 and @entity6 ), and showed migration toward @entity0 cells to a greater extent than the native MSCs. The bystander effect assay showed that the @entity5 /5-FC MSCs significantly augmented Cal72 @entity3 in direct co-culture and in the presence of 5-FC through the application of conditioned medium. In @entity4 -bearing @entity2 , the @entity5 /5-FC MSCs inhibited @entity1 growth when compared with control @entity2 subcutaneously injected with only @entity0 cells. CONCLUSIONS: Taken together, these findings suggest that @entity5 /5-FC MSCs may be suitable for targeting @entity0 @entity4 . This article is protected by copyright. All rights reserved.

title: Targeted inhibition of @entity4 growth by bone marrow-derived mesenchymal stem cells expressing cytosine deaminase/5-fluorocytosine in XXXX -bearing @entity2 .

answer: @entity1


abstract: BACKGROUND: Mesenchymal stem cells (MSCs) are considered an attractive approach for gene or drug delivery in @entity1 therapy. Thus, in this study, the ability of @entity0 bone marrow-derived MSCs expressing the cytosine deaminase/5-fluorocytosine prodrug ( @entity5 /5-FC MSCs) to target the @entity0 @entity4 cell line Cal72 was evaluated. METHODS: The stable @entity5 /5FC MSC cell line was established by transfection of pEGFP containing the cytosine deaminase gene into MSCs with G418 selection. The anti- @entity1 effect was verified by a bystander effect assay in vitro and co-injection of Cal72 and @entity5 /5FC MSCs in @entity1 -bearing @entity2 . RESULTS: The therapeutic @entity5 /5-FC MSCs retained the characteristics of multipotent cells such as differentiation into adipocytes/osteocytes and expression of mesenchymal markers ( @entity7 and @entity6 ), and showed migration toward @entity0 cells to a greater extent than the native MSCs. The bystander effect assay showed that the @entity5 /5-FC MSCs significantly augmented Cal72 @entity3 in direct co-culture and in the presence of 5-FC through the application of conditioned medium. In @entity4 -bearing @entity2 , the @entity5 /5-FC MSCs inhibited @entity1 growth when compared with control @entity2 subcutaneously injected with only @entity0 cells. CONCLUSIONS: Taken together, these findings suggest that @entity5 /5-FC MSCs may be suitable for targeting @entity0 @entity4 . This article is protected by copyright. All rights reserved.

title: Targeted inhibition of @entity4 growth by bone marrow-derived mesenchymal stem cells expressing cytosine deaminase/5-fluorocytosine in @entity1 -bearing XXXX .

answer: @entity2


abstract: UNASSIGNED: The objective of this study was to examine the association between sexual activities, problems and satisfaction, and @entity1 and @entity2 inhibitor (PDE5i) use. A nationally representative sample of @entity0 (n=2612) aged 51-87 years from the English Longitudinal Study of Ageing completed an in-depth Sexual Relationships and Activities Questionnaire. Associations between @entity1 and/or PDE5i use and sexual outcomes were explored using logistic regression models adjusted for age, health and lifestyle factors. PDE5i use in the preceding 3 months was reported by a total of 191 (7%) @entity0 , whereas 542 (21%) reported @entity1 but no PDE5i use (untreated @entity1 ). Compared with @entity0 without @entity1 , PDE5i users were more likely to be sexually active and report more frequent sexual intercourse. @entity0 with untreated @entity1 reported the lowest frequency of sexual activities. Compared with @entity0 without @entity1 , both PDE5i users and those with untreated @entity1 were more likely to report being concerned about their level of sexual desire, frequency of sexual activities, erectile function, waking erections and orgasmic experience. PDE5i users were also more concerned about and dissatisfied with their overall sex life than @entity0 without @entity1 . This population-based study shows that while PDE5i use is associated with improved sexual functioning, this is not equally reflected in decreased levels of concern and dissatisfaction with their overall sexual health. Clinicians should be aware of this disparity between functional gains and continuing sexual concerns and dissatisfaction, and, where appropriate, offer psychosexual counselling as an adjunct to PDE5i medication.

title: Erectile dysfunction and phosphodiesterase type 5 inhibitor use: associations with sexual activities, function and satisfaction in a population sample of older XXXX .

answer: @entity0


abstract: @entity2 ( @entity2 ) is a potent stimulator of bone resorption. Induction of osteoclastic bone resorption by various endocrine or paracrine factors is mediated via the osteoblasts. We have therefore investigated the effects of @entity3 on cell signalling in isolated @entity0 osteoblasts. Special interest was focused on @entity7 synthesis, since @entity8 , an inhibitor of @entity7 synthesis, partly inhibits @entity2 -induced bone resorption. @entity3 , at and above 0.3 pM, dose dependently stimulated @entity4 formation in isolated @entity0 osteoblasts, with half maximal stimulation, EC50, at 3 pM. Treatment with the @entity1 ionophore @entity9 (1 microM), or with @entity6 (30 microM), also stimulated @entity4 formation in @entity0 osteoblasts. The time-course for @entity3 -induced @entity4 formation was similar to that of @entity6 , with a significant increase in the formation of @entity4 seen after 1 h. In contrast, @entity9 -induced @entity4 formation was seen within minutes. @entity3 stimulated the accumulation of @entity5 in isolated @entity0 osteoblasts incubated for 15 min. This increase in @entity5 formation was not secondary to @entity4 formation since it was not blocked by the addition of @entity8 (1 microM). Pretreatment with the phosphodiesterase inhibitor IBMX did not augment @entity3 -induced @entity4 formation, nor did the protein kinase A inhibitor @entity10 inhibit @entity3 -induced @entity4 formation, suggesting that @entity5 does not mediate the stimulatory effect of @entity2 on @entity4 formation. We conclude that @entity3 enhances the formation of @entity5 as well as @entity4 in primary cultures of isolated @entity0 osteoblasts. The @entity3 -induced @entity5 formation is, however, not related to the enhanced @entity7 formation. The findings implicate that both @entity5 - and @entity4 -formation in osteoblasts might be involved as independent mediators of @entity3 -induced bone resorption.

title: @entity3 induces XXXX formation in isolated @entity0 osteoblasts: a signalling mechanism that is not related to enhanced @entity7 formation.

answer: @entity5


abstract: @entity2 ( @entity2 ) is a potent stimulator of bone resorption. Induction of osteoclastic bone resorption by various endocrine or paracrine factors is mediated via the osteoblasts. We have therefore investigated the effects of @entity3 on cell signalling in isolated @entity0 osteoblasts. Special interest was focused on @entity7 synthesis, since @entity8 , an inhibitor of @entity7 synthesis, partly inhibits @entity2 -induced bone resorption. @entity3 , at and above 0.3 pM, dose dependently stimulated @entity4 formation in isolated @entity0 osteoblasts, with half maximal stimulation, EC50, at 3 pM. Treatment with the @entity1 ionophore @entity9 (1 microM), or with @entity6 (30 microM), also stimulated @entity4 formation in @entity0 osteoblasts. The time-course for @entity3 -induced @entity4 formation was similar to that of @entity6 , with a significant increase in the formation of @entity4 seen after 1 h. In contrast, @entity9 -induced @entity4 formation was seen within minutes. @entity3 stimulated the accumulation of @entity5 in isolated @entity0 osteoblasts incubated for 15 min. This increase in @entity5 formation was not secondary to @entity4 formation since it was not blocked by the addition of @entity8 (1 microM). Pretreatment with the phosphodiesterase inhibitor IBMX did not augment @entity3 -induced @entity4 formation, nor did the protein kinase A inhibitor @entity10 inhibit @entity3 -induced @entity4 formation, suggesting that @entity5 does not mediate the stimulatory effect of @entity2 on @entity4 formation. We conclude that @entity3 enhances the formation of @entity5 as well as @entity4 in primary cultures of isolated @entity0 osteoblasts. The @entity3 -induced @entity5 formation is, however, not related to the enhanced @entity7 formation. The findings implicate that both @entity5 - and @entity4 -formation in osteoblasts might be involved as independent mediators of @entity3 -induced bone resorption.

title: XXXX induces @entity5 formation in isolated @entity0 osteoblasts: a signalling mechanism that is not related to enhanced @entity7 formation.

answer: @entity3


abstract: @entity2 ( @entity2 ) is a potent stimulator of bone resorption. Induction of osteoclastic bone resorption by various endocrine or paracrine factors is mediated via the osteoblasts. We have therefore investigated the effects of @entity3 on cell signalling in isolated @entity0 osteoblasts. Special interest was focused on @entity7 synthesis, since @entity8 , an inhibitor of @entity7 synthesis, partly inhibits @entity2 -induced bone resorption. @entity3 , at and above 0.3 pM, dose dependently stimulated @entity4 formation in isolated @entity0 osteoblasts, with half maximal stimulation, EC50, at 3 pM. Treatment with the @entity1 ionophore @entity9 (1 microM), or with @entity6 (30 microM), also stimulated @entity4 formation in @entity0 osteoblasts. The time-course for @entity3 -induced @entity4 formation was similar to that of @entity6 , with a significant increase in the formation of @entity4 seen after 1 h. In contrast, @entity9 -induced @entity4 formation was seen within minutes. @entity3 stimulated the accumulation of @entity5 in isolated @entity0 osteoblasts incubated for 15 min. This increase in @entity5 formation was not secondary to @entity4 formation since it was not blocked by the addition of @entity8 (1 microM). Pretreatment with the phosphodiesterase inhibitor IBMX did not augment @entity3 -induced @entity4 formation, nor did the protein kinase A inhibitor @entity10 inhibit @entity3 -induced @entity4 formation, suggesting that @entity5 does not mediate the stimulatory effect of @entity2 on @entity4 formation. We conclude that @entity3 enhances the formation of @entity5 as well as @entity4 in primary cultures of isolated @entity0 osteoblasts. The @entity3 -induced @entity5 formation is, however, not related to the enhanced @entity7 formation. The findings implicate that both @entity5 - and @entity4 -formation in osteoblasts might be involved as independent mediators of @entity3 -induced bone resorption.

title: @entity3 induces @entity5 formation in isolated @entity0 osteoblasts: a signalling mechanism that is not related to enhanced XXXX formation.

answer: @entity7


abstract: @entity2 ( @entity2 ) is a potent stimulator of bone resorption. Induction of osteoclastic bone resorption by various endocrine or paracrine factors is mediated via the osteoblasts. We have therefore investigated the effects of @entity3 on cell signalling in isolated @entity0 osteoblasts. Special interest was focused on @entity7 synthesis, since @entity8 , an inhibitor of @entity7 synthesis, partly inhibits @entity2 -induced bone resorption. @entity3 , at and above 0.3 pM, dose dependently stimulated @entity4 formation in isolated @entity0 osteoblasts, with half maximal stimulation, EC50, at 3 pM. Treatment with the @entity1 ionophore @entity9 (1 microM), or with @entity6 (30 microM), also stimulated @entity4 formation in @entity0 osteoblasts. The time-course for @entity3 -induced @entity4 formation was similar to that of @entity6 , with a significant increase in the formation of @entity4 seen after 1 h. In contrast, @entity9 -induced @entity4 formation was seen within minutes. @entity3 stimulated the accumulation of @entity5 in isolated @entity0 osteoblasts incubated for 15 min. This increase in @entity5 formation was not secondary to @entity4 formation since it was not blocked by the addition of @entity8 (1 microM). Pretreatment with the phosphodiesterase inhibitor IBMX did not augment @entity3 -induced @entity4 formation, nor did the protein kinase A inhibitor @entity10 inhibit @entity3 -induced @entity4 formation, suggesting that @entity5 does not mediate the stimulatory effect of @entity2 on @entity4 formation. We conclude that @entity3 enhances the formation of @entity5 as well as @entity4 in primary cultures of isolated @entity0 osteoblasts. The @entity3 -induced @entity5 formation is, however, not related to the enhanced @entity7 formation. The findings implicate that both @entity5 - and @entity4 -formation in osteoblasts might be involved as independent mediators of @entity3 -induced bone resorption.

title: @entity3 induces @entity5 formation in isolated XXXX osteoblasts: a signalling mechanism that is not related to enhanced @entity7 formation.

answer: @entity0


abstract: Unilateral internal carotid artery (ICA) @entity5 may be accompanied by widespread @entity4 of extra- and intracranial vessels leading to subtle @entity2 . We applied multichannel recording of @entity6 in 28 @entity0 (68.3 +/- 8.1 years; 15 asymptomatic, 13 with a history of @entity1 ( @entity1 )) and compared them with an age- and sex-matched control group. All underwent a visual "odd-ball paradigm" as well as a psychometric test, the Cognitive Performance Test (CPT), testing mainly visual attention and memory. The potentials were derived from 16 electrodes according to the 10/20 system against linked mastoids. The latencies and amplitudes of N250 and @entity6 were measured and their amplitudes additionally mapped. Furthermore, the early sensory exogenous potentials, @entity7 , within the @entity6 potentials as well as conventional pattern reversal visual evoked potentials (PVEPs) were evaluated. (1) Both the early exogenous potentials and the conventional PVEPs showed no significant differences among all groups. (2) There were no significant differences between asymptomatic @entity0 and those with a @entity1 history in all parameters of the @entity6 complex so that one total @entity0 group was constructed and compared to the controls. (3) @entity0 ' @entity6 amplitudes showed significant reductions over hemispheres ipsilateral (P < or = 0.014) and contralateral (P < or = 0.044) to the @entity5 . (4) The N250 amplitudes were reduced only in the central leads (P < or = 0.05). (5) The latencies of N250 potentials were significantly prolonged at many electrodes, not only ipsi-(P < or = 0.0007) but also contralateral (P < or = 0.022) to the @entity5 . (6) The @entity0 ' @entity6 latencies showed significant lengthening only at occipital sites (P < or = 0.05) compared to controls. (7) In all measured parameters, within the @entity0 group, the differences between hemispheres ipsilateral versus contralateral to the ICA stenoses did not reach statistical significance. (8) The CPT values detected slight @entity2 for both @entity0 groups and they correlated significantly with the latencies in many leads. (9) The highest test sensitivity to classify @entity0 versus controls (z score > 2) was reached in @entity6 maps of @entity1 @entity0 (77%). An altered @entity6 indicates electrophysiologically, and @entity2 , subclinical @entity2 even in asymptomatic @entity0 with unilateral tight ICA stenoses. Interestingly, no differences between asymptomatic and @entity1 @entity0 with a high-grade @entity3 could be found.

title: Symptomatic and asymptomatic high-grade unilateral internal carotid artery XXXX : scalp topography of event-related potentials ( @entity6 ) and psychometric testing.

answer: @entity5


abstract: Unilateral internal carotid artery (ICA) @entity5 may be accompanied by widespread @entity4 of extra- and intracranial vessels leading to subtle @entity2 . We applied multichannel recording of @entity6 in 28 @entity0 (68.3 +/- 8.1 years; 15 asymptomatic, 13 with a history of @entity1 ( @entity1 )) and compared them with an age- and sex-matched control group. All underwent a visual "odd-ball paradigm" as well as a psychometric test, the Cognitive Performance Test (CPT), testing mainly visual attention and memory. The potentials were derived from 16 electrodes according to the 10/20 system against linked mastoids. The latencies and amplitudes of N250 and @entity6 were measured and their amplitudes additionally mapped. Furthermore, the early sensory exogenous potentials, @entity7 , within the @entity6 potentials as well as conventional pattern reversal visual evoked potentials (PVEPs) were evaluated. (1) Both the early exogenous potentials and the conventional PVEPs showed no significant differences among all groups. (2) There were no significant differences between asymptomatic @entity0 and those with a @entity1 history in all parameters of the @entity6 complex so that one total @entity0 group was constructed and compared to the controls. (3) @entity0 ' @entity6 amplitudes showed significant reductions over hemispheres ipsilateral (P < or = 0.014) and contralateral (P < or = 0.044) to the @entity5 . (4) The N250 amplitudes were reduced only in the central leads (P < or = 0.05). (5) The latencies of N250 potentials were significantly prolonged at many electrodes, not only ipsi-(P < or = 0.0007) but also contralateral (P < or = 0.022) to the @entity5 . (6) The @entity0 ' @entity6 latencies showed significant lengthening only at occipital sites (P < or = 0.05) compared to controls. (7) In all measured parameters, within the @entity0 group, the differences between hemispheres ipsilateral versus contralateral to the ICA stenoses did not reach statistical significance. (8) The CPT values detected slight @entity2 for both @entity0 groups and they correlated significantly with the latencies in many leads. (9) The highest test sensitivity to classify @entity0 versus controls (z score > 2) was reached in @entity6 maps of @entity1 @entity0 (77%). An altered @entity6 indicates electrophysiologically, and @entity2 , subclinical @entity2 even in asymptomatic @entity0 with unilateral tight ICA stenoses. Interestingly, no differences between asymptomatic and @entity1 @entity0 with a high-grade @entity3 could be found.

title: Symptomatic and asymptomatic high-grade unilateral internal carotid artery @entity5 : scalp topography of event-related potentials ( XXXX ) and psychometric testing.

answer: @entity6


abstract: OBJECTIVE: To assess the efficacy of @entity3 , @entity1 , and combination therapy of both agents for the treatment of ureteral stent-related symptoms (SRSs). METHODS: An open-label, randomized controlled trial was conducted with 112 @entity0 who underwent unilateral ureteral stent insertion following ureteroscopic stone surgery. @entity0 were randomized with a 2  *  2 factorial design to one of four groups, i.e., A (control), B ( @entity3 0.2  mg once daily), C ( @entity1 5  mg once daily), and D (both active treatments). @entity0 were evaluated at week 2 by the ureteral stent symptom questionnaire (USSQ). The primary efficacy outcome was the urinary symptom score of the USSQ, and the secondary efficacy outcomes were the scores in the other five USSQ domains, the @entity2 -QOL score, and oral analgesic requirements during the 2  weeks. Efficacy outcomes were primarily analyzed for the per-protocol set population. RESULTS: The four groups were generally well balanced in terms of baseline characteristics. Eighty-one @entity0 (72.3  %) completed the study protocol. Comparison of the six USSQ domain scores at week 2 showed no differences between the four groups. Similarly, comparison of the domain scores stratified by @entity3 or @entity1 medication showed no differences for either medication. The other secondary outcomes were also similar in the group comparisons. CONCLUSIONS: Neither @entity3 nor @entity1 medications provide beneficial effects for relieving various SRSs. In addition, the combination therapy did not have beneficial effects. Further studies are warranted to determine the benefit of medical therapy for the treatment of SRSs and to determine the optimal management strategy for SRSs.

title: A critical assessment of the effects of XXXX and @entity1 as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2  *  2 factorial randomized trial.

answer: @entity3


abstract: OBJECTIVE: To assess the efficacy of @entity3 , @entity1 , and combination therapy of both agents for the treatment of ureteral stent-related symptoms (SRSs). METHODS: An open-label, randomized controlled trial was conducted with 112 @entity0 who underwent unilateral ureteral stent insertion following ureteroscopic stone surgery. @entity0 were randomized with a 2  *  2 factorial design to one of four groups, i.e., A (control), B ( @entity3 0.2  mg once daily), C ( @entity1 5  mg once daily), and D (both active treatments). @entity0 were evaluated at week 2 by the ureteral stent symptom questionnaire (USSQ). The primary efficacy outcome was the urinary symptom score of the USSQ, and the secondary efficacy outcomes were the scores in the other five USSQ domains, the @entity2 -QOL score, and oral analgesic requirements during the 2  weeks. Efficacy outcomes were primarily analyzed for the per-protocol set population. RESULTS: The four groups were generally well balanced in terms of baseline characteristics. Eighty-one @entity0 (72.3  %) completed the study protocol. Comparison of the six USSQ domain scores at week 2 showed no differences between the four groups. Similarly, comparison of the domain scores stratified by @entity3 or @entity1 medication showed no differences for either medication. The other secondary outcomes were also similar in the group comparisons. CONCLUSIONS: Neither @entity3 nor @entity1 medications provide beneficial effects for relieving various SRSs. In addition, the combination therapy did not have beneficial effects. Further studies are warranted to determine the benefit of medical therapy for the treatment of SRSs and to determine the optimal management strategy for SRSs.

title: A critical assessment of the effects of @entity3 and XXXX as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2  *  2 factorial randomized trial.

answer: @entity1


abstract: UNASSIGNED: Stimulating the dorsal anterior pretectal nucleus (dAPtN) in @entity1 is more effective than stimulating the ventral APtN (vAPtN) at reducing tail-flick latency, whereas stimulation of the vAPtN is more effective at reducing @entity4 behavior. This study examines whether the cell lesion by injecting N-methyl-D-aspartate into the dAPtN or vAPtN changes the withdrawal threshold of a @entity1 hind paw during different phases of the tactile @entity2 induced by a @entity6 ( @entity6 ) of the contralateral sciatic nerve. The number of @entity5 immunoreactive cells in the APtN was also evaluated. The @entity1 whose vAPtN was lesioned 2 days before @entity6 had more intense tactile @entity2 2 days after @entity6 than that of the control, but the groups were not different 7 days after the @entity6 . The @entity1 whose vAPtN was lesioned 5 days after @entity6 had WTs that did not significantly differ 7 days after the @entity6 . The tactile @entity2 of the @entity1 whose dAPtN was lesioned 2 days before or 5 days after @entity6 was not different from that of the control on the 2(nd) and 7(th) days after the @entity6 . The number of @entity5 immunoreactive cells in the vAPtN and dAPtN increased 2 days after @entity6 , but did not differ from that in the control 7 days after @entity6 . We conclude that vAPtN and dAPtN cells are activated by @entity3 ; the vAPtN exerts inhibitory control of the initial phase of @entity0 whereas the dAPtN does not appear to exert inhibitory role in neuropathic processing. This article is protected by copyright. All rights reserved.

title: The ventral portion of the anterior pretectal nucleus controls descending mechanisms that initiate XXXX in @entity1 .

answer: @entity0


abstract: UNASSIGNED: Stimulating the dorsal anterior pretectal nucleus (dAPtN) in @entity1 is more effective than stimulating the ventral APtN (vAPtN) at reducing tail-flick latency, whereas stimulation of the vAPtN is more effective at reducing @entity4 behavior. This study examines whether the cell lesion by injecting N-methyl-D-aspartate into the dAPtN or vAPtN changes the withdrawal threshold of a @entity1 hind paw during different phases of the tactile @entity2 induced by a @entity6 ( @entity6 ) of the contralateral sciatic nerve. The number of @entity5 immunoreactive cells in the APtN was also evaluated. The @entity1 whose vAPtN was lesioned 2 days before @entity6 had more intense tactile @entity2 2 days after @entity6 than that of the control, but the groups were not different 7 days after the @entity6 . The @entity1 whose vAPtN was lesioned 5 days after @entity6 had WTs that did not significantly differ 7 days after the @entity6 . The tactile @entity2 of the @entity1 whose dAPtN was lesioned 2 days before or 5 days after @entity6 was not different from that of the control on the 2(nd) and 7(th) days after the @entity6 . The number of @entity5 immunoreactive cells in the vAPtN and dAPtN increased 2 days after @entity6 , but did not differ from that in the control 7 days after @entity6 . We conclude that vAPtN and dAPtN cells are activated by @entity3 ; the vAPtN exerts inhibitory control of the initial phase of @entity0 whereas the dAPtN does not appear to exert inhibitory role in neuropathic processing. This article is protected by copyright. All rights reserved.

title: The ventral portion of the anterior pretectal nucleus controls descending mechanisms that initiate @entity0 in XXXX .

answer: @entity1


abstract: UNASSIGNED: Candida auris is a multidrug resistant @entity2 that cause wide spectrum of @entity1 , especially in intensive care settings. We investigated C. auris prevalence among 102 clinical isolates previously identified as C. haemulonii or C. famata by VITEK2 system. ITS sequencing confirmed 88.2% of isolates as C. auris and matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI- @entity0 ) easily separated all related species viz., C. auris (n=90), C. haemulonii (n=6), C. haemulonii var. vulnera (n=1) and C. duobushaemulonii (n=5). The in vitro antifungal susceptibility was determined using CLSI-BMD, VITEK2 AST card and Etest method. C. auris isolates revealed uniformly elevated fluconazole MICs (MIC50, 64  g/ml) and an alarming percentage of isolates (37%) exhibited elevated caspofungin MICs by CLSI-BMD. Notably, 34% of C. auris had coexisting elevated MICs (>= 2  g/ml) for both fluconazole and voriconazole and 10% of the isolates had elevated coexisting MICs (>=  2  g/ml) to two additional azoles i.e., posaconazole and isavuconazole. In contrast to reduced amphotericin B MICs by CLSI-BMD (MIC50, 1  g/ml) for C. auris, elevated MICs were noted by VITEK2, (MIC50, 8  g/ml), which were statistically significant. Candida auris remains an unnoticed pathogen in routine microbiology laboratories as 90% of the isolates characterized by commercial identification systems are misidentified as C. haemulonii. MALDI- @entity0 proved to be a more robust diagnostic technique for rapid identification of C. auris. Considering that misleading elevated MICs of amphotericin B by VITEK AST-YS07 card may lead to selection of inappropriate therapy, a cautionary approach is recommended for laboratories relying on commercial systems for identification and antifungal susceptibility testing of rare @entity2 .

title: Multidrug resistant Candida auris misidentified as C. haemulonii: Characterization by Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI- XXXX MS), DNA sequencing and its antifungal susceptibility profile variability by VITEK-2, CLSI-Broth Microdilution and E-test method.

answer: @entity0


abstract: OBJECTIVE: To evaluate the antitumour effect of an angio-inhibitory drug, a synthetic analogue of @entity8 ( @entity7 ), on @entity2 @entity5 ( @entity5 ) in vivo and in vitro. MATERIALS AND METHODS: The effect of @entity7 on the growth of @entity5 cells in vitro was measured by angiogenesis assay and cell counting with dye exclusion. In the angiogenesis assay, @entity5 cells were injected intradermally and the number of blood vessels orientated towards the @entity1 was counted 3 days after @entity1 inoculation. To examine the effect of @entity7 on the subcutaneous @entity1 growth and lung @entity0 of @entity5 , @entity5 cells were injected subcutaneously or intravenously in BALB/c @entity2 and they were treated with a subcutaneous injection every 3 days. RESULTS: Dose-dependent growth inhibition in vitro was observed with 50% inhibition occurring at 600 ng/ml. Angiogenesis assay revealed that administration of @entity7 inhibited the angiogenesis induced by @entity5 in a dose-dependent manner. In the subcutaneous experiment, @entity7 decreased the growth rate of established subcutaneous @entity1 rather than reduced the size of the @entity1 . The administration of @entity7 in @entity2 with lung @entity0 inhibited the development of @entity0 of @entity5 without @entity4 or @entity3 . CONCLUSION: The present study demonstrated that @entity7 had an inhibitory effect on @entity1 -induced angiogenesis and a significant anti- @entity1 effect on @entity5 . This suggests that @entity7 could be useful in the treatment of @entity6 . Further studies are needed to clarify whether @entity7 is more effective when combined with other drugs such as interferons.

title: Antitumour effect of a synthetic analogue of XXXX on @entity2 @entity5 .

answer: @entity8


abstract: OBJECTIVE: To evaluate the antitumour effect of an angio-inhibitory drug, a synthetic analogue of @entity8 ( @entity7 ), on @entity2 @entity5 ( @entity5 ) in vivo and in vitro. MATERIALS AND METHODS: The effect of @entity7 on the growth of @entity5 cells in vitro was measured by angiogenesis assay and cell counting with dye exclusion. In the angiogenesis assay, @entity5 cells were injected intradermally and the number of blood vessels orientated towards the @entity1 was counted 3 days after @entity1 inoculation. To examine the effect of @entity7 on the subcutaneous @entity1 growth and lung @entity0 of @entity5 , @entity5 cells were injected subcutaneously or intravenously in BALB/c @entity2 and they were treated with a subcutaneous injection every 3 days. RESULTS: Dose-dependent growth inhibition in vitro was observed with 50% inhibition occurring at 600 ng/ml. Angiogenesis assay revealed that administration of @entity7 inhibited the angiogenesis induced by @entity5 in a dose-dependent manner. In the subcutaneous experiment, @entity7 decreased the growth rate of established subcutaneous @entity1 rather than reduced the size of the @entity1 . The administration of @entity7 in @entity2 with lung @entity0 inhibited the development of @entity0 of @entity5 without @entity4 or @entity3 . CONCLUSION: The present study demonstrated that @entity7 had an inhibitory effect on @entity1 -induced angiogenesis and a significant anti- @entity1 effect on @entity5 . This suggests that @entity7 could be useful in the treatment of @entity6 . Further studies are needed to clarify whether @entity7 is more effective when combined with other drugs such as interferons.

title: Antitumour effect of a synthetic analogue of @entity8 on @entity2 XXXX .

answer: @entity5